A surge in the stock of Aurora Cannabis Inc. (NASDAQ: ACB) is currently underway, with an increase of 21.54% to $3.87 at the latest observation. This surge, although occurring without any notable news, prompts an exploration of recent developments potentially driving this upswing.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aurora Cannabis (ACB), in collaboration with its subsidiary, MedReleaf Australia, has recently unveiled a new medical cannabis product in Australia: pastilles, available for prescription by physicians. This innovative offering, manufactured by Aurora and distributed through MedReleaf Australia, a prominent distributor of medical cannabis products holding the second position in the Australian market, signifies a noteworthy development.
Australia boasts the world’s largest nationally legal medical cannabis market. As a long-standing supplier to MedReleaf Australia and its recently announced parent company, Aurora is enthusiastic about contributing to the sustained growth and evolution of this market. The introduction of novel products like pastilles, alongside forthcoming innovations, will not only offer Australian doctors expanded treatment options but also improve patient access to premium medical cannabis.
MedReleaf Australia remains steadfast in its commitment to providing Australian patients with consistently superior-quality products, including dried flower, resin cartridges, oils, and now pastilles. These new pastille offerings, exclusively branded under Aurora, represent just the beginning, with plans for diverse pack sizes, potencies, and future offerings under the IndiMed brand.
Demonstrating a dedication to patients and the advancement of medical cannabis accessibility within the Australian program, ACB’s introduction of innovative products underscores its leading position in the industry. The availability of pre-dosed pastilles widens the spectrum of high-quality medical cannabis options, catering to patients who may prefer a discreet, portable, and cost-effective alternative to oils or flower due to taste considerations, thus enhancing their treatment regimen.
In a related development, Aurora recently declared its collaboration with Script Assist, a state-of-the-art medical cannabis prescription platform in the UK, through Aurora Medicine UK Ltd. High-quality medicine is accessible through the Script Assist platform’s portal, which is designed to help UK patients on their journey towards well-being.
A wide selection of medical cannabis products from Aurora’s impressive product line will be made available through Script Assist. Three recently introduced, premium hand-processed and hang-dried flower products from Aurora’s EU GMP facilities in Canada will also be available in the UK starting in March.
